Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D09GXF
|
||||
Former ID |
DIB014416
|
||||
Drug Name |
RB-105
|
||||
Synonyms |
S-21402; S-21402-1; N-[2(S)-(Mercaptomethyl)-3(R)-phenylbutyl]-L-alanine
|
||||
Drug Type |
Small molecular drug
|
||||
Structure |
Download2D MOL |
||||
Formula |
C14H19NO3S
|
||||
Canonical SMILES |
CC(C1=CC=CC=C1)C(CS)C(=O)NC(C)C(=O)O
|
||||
InChI |
1S/C14H19NO3S/c1-9(11-6-4-3-5-7-11)12(8-19)13(16)15-10(2)14(17)18/h3-7,9-10,12,19H,8H2,1-2H3,(H,15,16)(H,17,18)/t9-,10-,12-/m0/s1
|
||||
InChIKey |
ABBSOQIXYPZCKO-NHCYSSNCSA-N
|
||||
CAS Number |
CAS 155895-89-9
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Neutral endopeptidase | Target Info | Modulator | ||
Angiotensin-converting enzyme | Target Info | Modulator | |||
NetPath Pathway | EGFR1 Signaling Pathway | ||||
TGF_beta_Receptor Signaling Pathway | |||||
PathWhiz Pathway | Angiotensin Metabolism | ||||
References | |||||
Ref 1560271 | Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs. | ||||
Ref 1560277 | Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure. | ||||
Ref 1560322 | Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovolemia. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.